AUSTIN, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today commencement of a collaboration with a research team at Case Western Reserve University (CWRU) School of Medicine headed by leading gastroenterologist, Fabio Cominelli, M.D., Ph.D. Dr. Cominelli and his research team will conduct pre-clinical studies to help develop new treatments for Inflammatory Bowel Disease (IBD) using the company's pioneering approach to using natural human antibody therapy to neutralize harmful inflammation. Dr. Cominelli is a world-leading expert in inflammatory bowel disease. His group was the first to report that specific blockade of interleukin-1 (IL-1) was effective in reducing disease severity in colitis and that deregulated inflammation is a cause of auto-inflammatory diseases, including IBD. Dr. Cominelli is Chief of the Division of Gastroenterology and Liver Disease and Director of the Digestive Health Institute at CWRU School of Medicine in Cleveland and Chief Scientific Officer of the Digestive Health Institute at University Hospitals Cleveland Medical Center. Dr. Cominelli is also the Hermann Menges Jr. Chair in Internal Medicine and Professor at CWRU School of Medicine. Dr. Cominelli has a professional interest in Crohn's disease, gastrointestinal (GI) cancer, IBD and ulcerative colitis. He is a member of the American Society for Clinical Investigation and Association of American Physicians. He has previously earned a NIH Merit Award. His work has been published in a number of peer-reviewed journals, such as Inflammatory Bowel Diseases and The Journal of Immunology. Dr. Cominelli earned his medical degree at Universita' Degli Studi di Firenze in Florence, Italy, where he also completed his internal medicine residency. He completed his gastroenterology fellowship at Harbor-UCLA Medical Center in Torrance, California. Dr. Cominelli stated, "I have researched IL-1's role in disease severity in colitis for many years, and am excited about the opportunity to be able to selectively inhibit IL-1 alpha to better define its role in IBD. These results will help shape the design of future clinical trials as we look for new and better treatments for this wide-spread condition."